SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 248.01 |
| Enterprise Value ($M) | 243.88 |
| Book Value ($M) | 47.96 |
| Book Value / Share | 1.12 |
| Price / Book | 5.17 |
| NCAV ($M) | 46.21 |
| NCAV / Share | 1.08 |
| Price / NCAV | 5.37 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.45 |
| Return on Assets (ROA) | -0.40 |
| Return on Equity (ROE) | -0.43 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 11.81 |
| Current Ratio | 11.81 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 50.77 |
| Assets | 52.52 |
| Liabilities | 4.56 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Dialectic Capital Management, Lp | 5.20 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 23,407 | 106,471 | 21.98 | |
| 27,517 | 119,335 | 23.06 | |
| 21,654 | 247,158 | 8.76 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| CYTH – Cyclo Therapeutics, Inc. | DARE – Daré Bioscience, Inc. |
| DERM – Journey Medical Corporation | DNTH – Dianthus Therapeutics, Inc. |
| DRMA – Dermata Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io